Trial Profile
MSBase- An international Registry dedicated to evaluating outcomes data in Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Glatiramer acetate; Interferon
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MSBase
- 13 Oct 2023 Results evaluating the comparative effectiveness of ocrelizumab, a high efficacy DMT, versus interferon or glatiramer acetate in pwMS over the age of 60, are presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
- 13 Oct 2023 Results by identifying patients from this study to explore relapse and disability outcomes comparing those retreated with 3rd cycle of alemtuzumab vs those receiving different high efficacy DMT (ocrelizumab,ofatumumab, natalizumab),stratifying by time from 2nd alemtuzumab cycle to the next relapse, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 09 Nov 2022 Results analyzing cost effectiveness by deriving data from GLIMPSE, a real-world study evaluating treatment effectiveness of these oral DMTs in RMS patients in MSBase registry, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research